Asset Details
Do you wish to reserve the book?
Cost-effectiveness analysis of two inhaled antibiotics for stable Bronchiectasis with Pseudomonas aeruginosa infections in China
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cost-effectiveness analysis of two inhaled antibiotics for stable Bronchiectasis with Pseudomonas aeruginosa infections in China
Do you wish to request the book?
Cost-effectiveness analysis of two inhaled antibiotics for stable Bronchiectasis with Pseudomonas aeruginosa infections in China
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cost-effectiveness analysis of two inhaled antibiotics for stable Bronchiectasis with Pseudomonas aeruginosa infections in China
2025
Overview
To evaluate the cost-effectiveness of two available options for inhaled antibiotic treatment for patients with Bronchiectasis (BE) with Pseudomonas aeruginosa (PA) infections from the perspective of China's healthcare system.
A four-state Markov model was developed over a one-year horizon to simulate the cost-effectiveness of two inhaled antibiotic strategies: Tobramycin inhalation solution (TIS) versus nebulized colistimethate sodium (CMS). The inputs for the model were derived from phase III clinical trials and published literature, with cost data were sourced from public and real-world databases, etc. The incremental cost-effectiveness ratio (ICER) was assessed, setting the willingness-to-pay threshold at one times the per capita GDP of China. Scenario and sensitivity analyses were performed to explore the impact of uncertainties in input parameters.
Over a one-year period, TIS was found to dominate CMS, resulting in a cost saving of CNY 41,109.53 (USD 5,689.27) and an increase of 0.0048 quality-adjusted life years (QALYs) per patient. Sensitivity analyses confirmed the robustness of these findings, which remained consistent under various scenarios.
TIS reduces healthcare costs and improves clinical outcomes compared to CMS in managing BE with PA infections in China. This study supports the inclusion of TIS in clinical guidelines for managing BE with PA infections, considering both economic benefits and health outcomes.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Analysis
/ Anti-Bacterial Agents - administration & dosage
/ Anti-Bacterial Agents - economics
/ Anti-Bacterial Agents - therapeutic use
/ Bronchiectasis - complications
/ Bronchiectasis - drug therapy
/ Bronchiectasis - microbiology
/ China
/ Colistin - administration & dosage
/ Colistin - analogs & derivatives
/ Humans
/ Medicine and Health Sciences
/ Patients
/ Pseudomonas aeruginosa - drug effects
/ Pseudomonas aeruginosa infections
/ Pseudomonas Infections - complications
/ Pseudomonas Infections - drug therapy
/ Pseudomonas Infections - economics
/ Sodium
